<DOC>
	<DOCNO>NCT02219880</DOCNO>
	<brief_summary>The use Kava Generalised Anxiety Disorder : 18-week double-blind , randomise , placebo-controlled study .</brief_summary>
	<brief_title>Kava Treatment Generalised Anxiety Disorder : A Double-Blind Randomised Placebo-Controlled Trial</brief_title>
	<detailed_description>The primary aim confirm efficacy safety Kava compare placebo Generalized Anxiety Disorder ( GAD ) . Secondary aim study confirm relationship specific genetic variation response Kava , explore effect Kava expression specific gene . Consenting participant randomly allocate take either Kava placebo 18 week . They assess regular interview throughout trial four blood test ( liver function test monitor participant safety , collection genetic material provide information neurochemistry ) . The design study multi-centre , 18-week , 2-arm , double-blind randomise clinical trial ( RCT ) use standardise pharmaceutical-grade water-soluble extract Kava ( 240mg kavalactones per day ) versus placebo 210 adult GAD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>To consider inclusion study , participant require meet follow criterion : Aged 1870 year Meets Diagnostic Statistical Manual ( DSM ) IV DSMV diagnostic criterion generalise anxiety disorder ( GAD ) base structure interview ( Mini International Neuropsychiatric InterviewPlus 6 [ MINIPlus 6 ] . Note MINIPlus 6 us DSMIV criterion , criterion use DSMV ) . Presents anxiety ( Hamilton Anxiety Rating Scale ≥ 18 ) time study entry Fluent write spoken English Provides sign copy consent form Participants ineligible enter trial follow condition : Primary diagnosis GAD Presentation moderate severe depressive symptom ( MontgomeryAsberg Rating Scale : MADRS ≥ 18 time study entry ≥ 24 time study ) Presentation suicidal ideation ( ≥ 3 MADRS suicidal thought domain time study entry time study ) Current diagnosis bipolar disorder schizophrenia structure interview ( MINI Plus ) Current substance/alcohol use disorder structure interview ( MINI Plus ) Page 21 39 CommercialinConfidence Currently take antidepressant , mood stabiliser , antipsychotic , anticonvulsant , warfarin thyroxin , current regular use ( 2 day per week ) benzodiazepine opioidbased analgesic Current use psychotropic nutraceutical ( e.g . St John 's wort ) Previous intolerance kava Three fail trial pharmacotherapy current GAD episode Recently commence psychotherapy ( within four week study entry ) Known suspect clinically unstable systemic medical disorder Diagnosed hepatobiliary disease/inflammation Elevated liver enzymes baseline blood test Pregnancy breastfeeding , try conceive Not use medically approve contraception ( include abstinence ) female childbearing age Unable participate schedule visit , treatment plan , trial procedure accord protocol ( except optional genetic component )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Kava</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Psychiatric</keyword>
	<keyword>Anxiolytic</keyword>
	<keyword>GABA</keyword>
	<keyword>Kavalactones</keyword>
</DOC>